The panel includes both RNA-based and DNA-based viruses in one kit with 41,047 nucleic acid probes. It allows researchers to separate COVID-19 symptoms from those of other respiratory illnesses, both influenza- and non-influenza-related.
The direct-to-patient collection kit must still be ordered by a licensed healthcare provider and clinicians can visit the online GeneSight portal to request that a kit be sent directly to the patient.
Sema4 Signal is a family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment.
The PD-L1 assay and the AccuCyte-CyteFinder system processes a single tube of blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis.
COVID-19 Compass is based on CDC guidelines, best clinical practices, illness severity, and risk factors such as age, gender, location, potential exposure and pre-existing health conditions.
EsoGuard is designed to facilitate the diagnosis of Barrett’s Esophagus (BE) and related precursors to highly lethal esophageal adenocarcinoma (EAC).
Using the kit, researchers can capture the complete transcriptome, including short (<200 bp) and long (>200 bp) RNAs, in a single library prep.
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
Each of the new panels comes with ERASE-Seq, Fluxion's variant caller which uses statistical analysis to compare sequencing results across several molecular amplification pools.